Tilray | TRLY - Cost Of Sales

Stock Price
9.33
Daily Change
0.34 3.78%
Monthly
-6.42%
Yearly
1,144.00%
Q2 Forecast
8.92

Tilray reported $164.37M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Avita Medical AUD 3.3M 166K Dec/2025
Canopy Growth CAD 53.08M 8.3M Dec/2025
Cronos Group USD 28.74M 10.38M Dec/2025
Divis Laboratories Ltd INR 10.63B 1.23B Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
IQVIA Holdings USD 3.24B 518M Dec/2025
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Moderna USD 452M 245M Dec/2025
Organigram Holdings CAD 56.93M 20.53M Dec/2025
Organon & Co USD 745M 25M Sep/2025
Revvity USD 350.4M 26.05M Dec/2025
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.56B 167.3M Dec/2025
Xeris Pharmaceuticals USD 13.66M 49K Dec/2025
Zealand Pharma A/S 410K 5K Jun/2025